Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI0CX8
|
|||
| Drug Name |
AVT02
|
|||
| Synonyms |
adalimumab biosimilar
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0; ICD-9: 696] | Phase 3 | [1] | |
| Company |
Alvotech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03849404) A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira? in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS). U.S.National Institutes of Health. | |||
| REF 2 | AVT02: An Adalimumab Biosimilar. Clin Drug Investig. 2022 Oct;42(10):875-878. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.